Research Topics
| Robert C OwensSummaryAffiliation: Maine Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Antimicrobial stewardship: application in the intensive care unitRobert C Owens
Department of Clinical Pharmacy Services and Division of Infectious Diseases, Maine Medical Center, 22 Bramhall Street, Portland, ME 04102, USA
Infect Dis Clin North Am 23:683-702. 2009..With pharmacists and physicians trained in infectious disease and critical care, clear-cut interventions can be focused on beginning or growing a stewardship program, or proposing future studies...
Clostridium difficile-associated disease: changing epidemiology and implications for managementRobert C Owens
Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, Maine 04102, USA
Drugs 67:487-502. 2007..Several newer therapies are under investigation but it is unclear whether they will be superior to current treatment options...
Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic eraRobert C Owens
Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
Diagn Microbiol Infect Dis 57:77S-83S. 2007..In addition, general pharmacokinetic-pharmacodynamic (PK-PD) concepts will be reviewed and specific PK-PD analyses that support the optimal selection, dosing, and duration of therapy for beta-lactam antimicrobials will be provided...
Antimicrobial-associated QT interval prolongation: pointes of interestRobert C Owens
Department of Clinical Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
Clin Infect Dis 43:1603-11. 2006..Additionally, because TdP remains a difficult-to-measure adverse event, we must rely upon multiple data sources to determine the risk versus the benefit for newly approved drugs...
Antimicrobial stewardship: concepts and strategies in the 21st centuryRobert C Owens
Department of Clinical Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
Diagn Microbiol Infect Dis 61:110-28. 2008..The components of an effective ASP are described in depth, drawing examples from the literature, as well as from the author's personal experience at the Maine Medical Center, Portland, ME...
Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases PharmacistsRobert C Owens
Antimicrobial Stewardship Program, Departments of Pharmacy Services and Infectious Diseases, Maine Medical Center, Portland, Maine 04102, USA
Pharmacotherapy 26:299-311. 2006..difficile-associated disease. Efforts to combat BI/NAP1 should include good antimicrobial stewardship in addition to effective infection control and environmental intervention...
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?Robert C Owens
Department of Clinical Pharmacy and Infectious Diseases, Maine Medical Center, Bramhall Street, Portland, Maine 04102, USA
Crit Care 12:S3. 2008..Finally, new methods of administration are being evaluated that may influence peak concentration-related antimicrobial adverse events...
Antimicrobial stewardship: shepherding precious resourcesRobert C Owens
Department of Pharmacy, and Clinical Pharmacy Specialist, Infectious Diseases, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102 3175, USA
Am J Health Syst Pharm 66:S15-22. 2009..Differences in antimicrobial stewardship program (ASP) strategies, evidences supporting the benefits of ASPs, barriers to implementing ASPs, and suggestions for overcoming the barriers are discussed...
Antimicrobial safety: focus on fluoroquinolonesRobert C Owens
Division of Infectious Diseases, Department of Clinical Pharmacy Services, Maine Medical Center, Portland, Maine 04102, USA
Clin Infect Dis 41:S144-57. 2005..This review summarizes safety and tolerability data for the quinolones...
Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniaeRobert C Owens
Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
Diagn Microbiol Infect Dis 51:45-9. 2005..Preferential use of pharmacodynamically potent agents over other alternatives may lead to improved clinical outcomes and decreased selection of fluoroquinolone-resistant pneumococci...
Antimicrobial stewardship programs as a means to optimize antimicrobial use. Insights from the Society of Infectious Diseases PharmacistsRobert C Owens
Departments of Clinical Pharmacy Services Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
Pharmacotherapy 24:896-908. 2004..We review the more recent literature concerning the impact of antimicrobial stewardship programs on costs, outcomes, and resistance and summarize important considerations for implementation of these programs...
QT prolongation with antimicrobial agents: understanding the significanceRobert C Owens
Department of Clinical Pharmacy, Maine Medical Center, Portland, 04102, USA
Drugs 64:1091-124. 2004..Incorporating information learned regarding QT interval-related adverse effects into the drug selection process may serve to minimise collateral iatrogenic toxicity...
Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategiesRobert C Owens
Department of Pharmacy, and Clinical Pharmacy Specialist, Infectious Diseases, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102 3175, USA
Am J Health Syst Pharm 66:S23-30. 2009....
Torsades de pointes associated with fluoroquinolonesRobert C Owens
Department of Clinical Pharmacy, Maine Medical Center, Portland 04102, USA
Pharmacotherapy 22:663-8; discussion 668-72. 2002..For moxifloxacin, levofloxacin, and gatifloxacin, the point must be clear that these agents should not be used in patients with risk factors predisposing them to TdP...
Clinical pharmacodynamics of quinolonesPaul G Ambrose
Division of Infectious Diseases, Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221, USA
Infect Dis Clin North Am 17:529-43. 2003..The maturation of antimicrobial PK-PD as a scientific discipline continues to accelerate and currently impacts clinical practice, drug development, and regulatory decision making...
Antimicrobial-associated risk factors for Clostridium difficile infectionRobert C Owens
Maine Medical Center, Portland, ME 04102, USA
Clin Infect Dis 46:S19-31. 2008....
Stability of cefepime and metronidazole prepared for simplified administration as a single productThomas D Nolin
Department of Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
Diagn Microbiol Infect Dis 56:179-84. 2006..These data suggest that therapeutic use of cefepime and metronidazole as a single intravenous admixture product is feasible and practical...
Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycinRobert C Owens
Maine Medical Center, Portland, Maine, USA
Am J Med 120:S6-12. 2007..10 days, P = 0.002). The results of this study support previously published reports and suggest that daptomycin is effective for the treatment of skin infections due to gram-positive pathogens...
Optimizing antimicrobial dosing in the critically ill patientJohn Goldberg
Department of Medicine, Division of Infectious Diseases, and Division of Critical Care Pharmacology, Maine Medical Center, Portland, Maine 04102, USA
Curr Opin Crit Care 8:435-40. 2002..In this review, we discuss some of the principles required to optimize antimicrobial dosing and recently obtained data regarding its application to the critically ill patient...
Optimizing formulary choices of the fluoroquinolonesRobert C Owens
Antimicrobial Stewardship Program and Clinical Pharmacy Specialist, Infectious Diseases, Maine Medical Center, Portland, USA
Manag Care Interface . 2005
Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in deathRobert C Owens
Division of Infectious Diseases, Department of Medicine, Maine Medical Center, Portland, Maine, USA
J Clin Microbiol 49:3406-8. 2011..Susceptibility results (reported on day 4) showed resistance to the initially selected regimen...
Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strainsWarren N Fawley
Department of Microbiology, General Infirmary, Old Medical School, Leeds, United Kingdom
Infect Control Hosp Epidemiol 28:920-5. 2007..To compare the effects of hospital cleaning agents and germicides on the survival of epidemic Clostridium difficile strains...
Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepimePaul G Ambrose
Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221 5831, USA
J Antimicrob Chemother 49:445-53. 2002..Moreover, sufficient clinical outcome data in infected patients exist and support these pharmacodynamic conclusions...
Fluoroquinolone-associated dysglycemias: a tale of two toxicitiesRobert C Owens
Pharmacotherapy 25:1291-5. 2005
An epidemic, toxin gene-variant strain of Clostridium difficileL Clifford McDonald
Epidemiology and Laboratory Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, USA
N Engl J Med 353:2433-41. 2005..difficile with increased virulence, resistance, or both...
Hospital-based strategies for combating resistanceRobert C Owens
Department of Medicine, University of Vermont College of Medicine, Burlington, USA
Clin Infect Dis 42:S173-81. 2006....
Measures to control and prevent Clostridium difficile infectionDale N Gerding
Hines Veterans Affairs Hospital, Hines, IL 60141, USA
Clin Infect Dis 46:S43-9. 2008..The efficacy of metronidazole or vancomycin prophylaxis to prevent CDI in patients who are receiving other antimicrobials is unproven, and treatment with these agents is ineffective against C. difficile in asymptomatic carriers...
Treatment of Clostridium difficile infectionDale N Gerding
Hines Veterans Affairs Hospital, Hines, IL 60141, USA
Clin Infect Dis 46:S32-42. 2008..difficile vaccine...
Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factorsJoseph S Bertino
Departments of Pharmacy Services and Medicine, Division of Clinical Pharmacology, Bassett Healthcare, Cooperstown, NY, 13326, USA
Clin Infect Dis 34:861-3. 2002..We report 4 cases of gatifloxacin-associated cardiac toxicity in patients with known risk factors for this adverse event...
AUIC in humans: a fact-based discussionGuy W Amsden
Ann Pharmacother 37:1518-21. 2003
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardshipTimothy H Dellit
Harborview Medical Center and the University of Washington, Seattle, USA
Clin Infect Dis 44:159-77. 2007
